Skip to main
LRMR
LRMR logo

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics has demonstrated a significant increase in median frataxin (FXN) expression, rising from 2.7 pg/ug at baseline to 13.44 pg/ug at the six-month mark, indicating a favorable response to CTI-1601 treatment. This increase surpasses the >50% expression observed in healthy volunteers, which highlights the potential effectiveness of the company's CPP technology platform. Additionally, the median improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) score of -2.20 points contrasts positively with a decline of +1.00 in the natural history population, further supporting the therapeutic potential of their lead product candidate.

Bears say

Larimar Therapeutics faces significant challenges highlighted by a median change of -2.20 points in the modified Friedreich's Ataxia Rating Scale (mFARS) at one year, which demonstrates worsening patient outcomes compared to the marginal improvement captured in the FACOMS natural history population. Additionally, the company's FY29 revenue estimates have been notably revised down from $659 million to $407 million, indicating growing concerns about its market potential and competitive positioning in the Friedreich’s Ataxia treatment space. This combination of disappointing clinical results and reduced financial outlook contributes to a negative sentiment regarding the stock's future performance.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.